Objective:To evaluate the effects of Huoxin Pill(活心丸,HXP)on cardiac fibrosis and heart failure(HF)in isoproterenol(ISO)-induced HF rats.Methods:Thirty Wistar rats were randomly divided into 5 groups including contr...Objective:To evaluate the effects of Huoxin Pill(活心丸,HXP)on cardiac fibrosis and heart failure(HF)in isoproterenol(ISO)-induced HF rats.Methods:Thirty Wistar rats were randomly divided into 5 groups including control,HF,isosorbide mononitrate(ISMN),HXP low(HXP-L),and HXP high(HXP-H)groups(n=6 for each group)according to the complete randomization method.Rats were pretreated with ISMN(5 mg/kg daily),low concentration of HXP(10 mg/kg daily)or high concentration of HXP(30 mg/kg daily)or equal volume of saline by intragastric administration for 1 week,followed by intraperitoneal injection of ISO(10 mg/kg,14 days),and continually intragastric administrated with above medicines or saline for additional 6 weeks.The effects of HXP treatment on the cardiac function,heart weight index(HWI),pathological changes,and collagen content were further assessed.Moreover,the role of HXP on activation of transforming growth factor-β1(TGF-β1)/Smads pathway was further explored using immunohistochemistry(IHC)and Westernblot assay.Results:HXP treatment significantly alleviated the decrease of ejection fraction(EF)and fractional shortening(FS),while decreased the elevation of left ventricular end-systolic volume(LVESV)in ISO-induced HF rats(P<0.05).Moreover,HXP treatment obviously attenuated the increase of HWI and serum level of creatine kinase MB(CK-MB,P<0.05),as well as pathological changes in ISO-induced HF rats.Further determination indicated that HXP treatment alleviated the elevation of collagenⅠand collagenⅢprotein expression in cardiac tissues of ISO-induced HF rats.Furthermore,HXP treatment significantly down-regulated the increase of TGF-β1 and p-Smad2/3 protein expression in cardiac tissues of HF rats(P<0.05),while did not affect the expression of total Smad2/3.Conclusions:HXP attenuated heart failure and cardiac fibrosis in ISO-induced HF rats by suppression of TGF-β1/Smad2/3 pathway.展开更多
目的观察活心丸(浓缩丸)治疗冠心病稳定性心绞痛的有效性及安全性。方法采用多中心、随机、双盲、安慰剂对照的临床研究,对131例冠心病稳定性心绞痛(气虚血瘀证)患者随机分组,分别采用活心丸(浓缩丸)或安慰剂进行治疗8周,其中48例进行...目的观察活心丸(浓缩丸)治疗冠心病稳定性心绞痛的有效性及安全性。方法采用多中心、随机、双盲、安慰剂对照的临床研究,对131例冠心病稳定性心绞痛(气虚血瘀证)患者随机分组,分别采用活心丸(浓缩丸)或安慰剂进行治疗8周,其中48例进行心电图平板运动试验,观察治疗前后心绞痛症状、硝酸甘油停减率、心电图平板运动试验(总运动时间、运动诱发ST段下降0.1 m V或出现心绞痛的时间、诱发心电图ST段最大下移程度、运动诱发心电图ST段下移超过0.1 m V的导联数、运动代谢当量)、西雅图心绞痛调查量表总评分、中医证候变化情况、炎性因子以及血脂。结果治疗后,试验组心绞痛症状总积分明显低于对照组(P<0.01),试验组硝酸甘油停减率明显高于对照组(P<0.01),试验组西雅图心绞痛量表总分明显高于对照组(P<0.01),试验组中医证候疗效明显高于对照组(P<0.01)。心电图平板运动试验,试验组的ST段下降≥0.1 m V导联数较治疗前的减少数量明显高于对照组(P<0.01)。试验组V4、V5、V6导联ST段最大下移幅度较对照组明显降低(P<0.05)。炎性因子与血脂指标组间均没有明显统计学差异(P>0.05)。试验组不良事件发生率与对照组相当。结论活心丸(浓缩丸)治疗冠心病稳定性心绞痛的效果显著优于对照组,且具有良好的安全性和耐受性。展开更多
基金Supported by the National Natural Science Foundation of China(No.81774135 and No.81302884)Science and Technology Major Project of Fujian Province(No.2019YZ014004)+1 种基金Natural Science Foundations of Fujian Province(No.2018J01884)Fujian Provincial Health and Family Planning Commission(No.2018-CX-42)。
文摘Objective:To evaluate the effects of Huoxin Pill(活心丸,HXP)on cardiac fibrosis and heart failure(HF)in isoproterenol(ISO)-induced HF rats.Methods:Thirty Wistar rats were randomly divided into 5 groups including control,HF,isosorbide mononitrate(ISMN),HXP low(HXP-L),and HXP high(HXP-H)groups(n=6 for each group)according to the complete randomization method.Rats were pretreated with ISMN(5 mg/kg daily),low concentration of HXP(10 mg/kg daily)or high concentration of HXP(30 mg/kg daily)or equal volume of saline by intragastric administration for 1 week,followed by intraperitoneal injection of ISO(10 mg/kg,14 days),and continually intragastric administrated with above medicines or saline for additional 6 weeks.The effects of HXP treatment on the cardiac function,heart weight index(HWI),pathological changes,and collagen content were further assessed.Moreover,the role of HXP on activation of transforming growth factor-β1(TGF-β1)/Smads pathway was further explored using immunohistochemistry(IHC)and Westernblot assay.Results:HXP treatment significantly alleviated the decrease of ejection fraction(EF)and fractional shortening(FS),while decreased the elevation of left ventricular end-systolic volume(LVESV)in ISO-induced HF rats(P<0.05).Moreover,HXP treatment obviously attenuated the increase of HWI and serum level of creatine kinase MB(CK-MB,P<0.05),as well as pathological changes in ISO-induced HF rats.Further determination indicated that HXP treatment alleviated the elevation of collagenⅠand collagenⅢprotein expression in cardiac tissues of ISO-induced HF rats.Furthermore,HXP treatment significantly down-regulated the increase of TGF-β1 and p-Smad2/3 protein expression in cardiac tissues of HF rats(P<0.05),while did not affect the expression of total Smad2/3.Conclusions:HXP attenuated heart failure and cardiac fibrosis in ISO-induced HF rats by suppression of TGF-β1/Smad2/3 pathway.
文摘目的观察活心丸(浓缩丸)治疗冠心病稳定性心绞痛的有效性及安全性。方法采用多中心、随机、双盲、安慰剂对照的临床研究,对131例冠心病稳定性心绞痛(气虚血瘀证)患者随机分组,分别采用活心丸(浓缩丸)或安慰剂进行治疗8周,其中48例进行心电图平板运动试验,观察治疗前后心绞痛症状、硝酸甘油停减率、心电图平板运动试验(总运动时间、运动诱发ST段下降0.1 m V或出现心绞痛的时间、诱发心电图ST段最大下移程度、运动诱发心电图ST段下移超过0.1 m V的导联数、运动代谢当量)、西雅图心绞痛调查量表总评分、中医证候变化情况、炎性因子以及血脂。结果治疗后,试验组心绞痛症状总积分明显低于对照组(P<0.01),试验组硝酸甘油停减率明显高于对照组(P<0.01),试验组西雅图心绞痛量表总分明显高于对照组(P<0.01),试验组中医证候疗效明显高于对照组(P<0.01)。心电图平板运动试验,试验组的ST段下降≥0.1 m V导联数较治疗前的减少数量明显高于对照组(P<0.01)。试验组V4、V5、V6导联ST段最大下移幅度较对照组明显降低(P<0.05)。炎性因子与血脂指标组间均没有明显统计学差异(P>0.05)。试验组不良事件发生率与对照组相当。结论活心丸(浓缩丸)治疗冠心病稳定性心绞痛的效果显著优于对照组,且具有良好的安全性和耐受性。
